Screener
Lineage Cell Therapeutics LCTX Q3 2025 earnings
Reported November 6, 2025 · After market close
Revenue$3.7MBeat by $1.7M
EPS-$0.13Miss by $0.11
Revenue estimate$2.0M
EPS estimate-$0.02
Next report
Nov 5, 2026 (in 2 months)Revenue estimate$1.3M
EPS estimate-$0.03
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Lineage Cell Therapeutics report Q3 2025 earnings?
- Lineage Cell Therapeutics (LCTX) reported Q3 2025 earnings on November 6, 2025 after market close.
- What were Lineage Cell Therapeutics's Q3 2025 revenue and EPS?
- Lineage Cell Therapeutics reported revenue of $3.7M and eps of $-0.13 for Q3 2025.
- Did Lineage Cell Therapeutics beat estimates in Q3 2025?
- Revenue beat the consensus estimate of $2.0M by $1.7M. EPS missed the consensus estimate of $-0.02 by $0.11.
- How did Lineage Cell Therapeutics's Q3 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 2.6% from $3.8M a year earlier and eps declined 550.0% from $-0.02.
- Where can I find Lineage Cell Therapeutics's Q3 2025 SEC filings?
- You can read the 8-K earnings release (0001193125-25-269534) and the 10-Q periodic report (0001193125-25-269599) directly on SEC EDGAR. The filing index links above go to sec.gov.
